Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis autonomic dysfunction cognition fatigue non-motor symptoms pain questionnaires sleep

Journal

Expert review of neurotherapeutics
ISSN: 1744-8360
Titre abrégé: Expert Rev Neurother
Pays: England
ID NLM: 101129944

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 24 9 2021
medline: 1 2 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

The burden of non-motor symptoms is a major determinant of quality of life and outcome in amyotrophic lateral sclerosis (ALS) and has profound negative effect also on caregivers. Non-motor symptoms in ALS include cognitive impairment, neurobehavioral symptoms, depression and anxiety, suicidal ideation, pain, disordered sleep, fatigue, weight loss and reduced appetite, and autonomic dysfunctions. This review summarizes the measures used for the assessment of non-motor symptoms and their properties and recaps the frequency and progression of these symptoms along the course of ALS. Non-motor symptoms in ALS represent a major component of the disease and span over several domains. These symptoms require a high level of medical attention and should be checked at each visit using ad hoc questionnaires and proactively treated. Several instruments assessing non-motor symptoms have been used in ALS. Specific screening questionnaires for non-motor symptoms can be used for monitoring patients during telehealth visits and for remote surveillance through sensors and apps installed on smartphones. Novel trials for non-motor symptoms treatment specifically designed for ALS are necessary to increase and refine the therapeutic armamentarium. Finally, scales assessing the most frequent and burdensome non-motor symptoms should be included in clinical trials.

Identifiants

pubmed: 34554894
doi: 10.1080/14737175.2021.1984883
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1419-1440

Auteurs

Adriano Chiò (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.
Neurology I, Azienda Ospedaliera Città Della Salute E Della Scienza of Turin, Turin, Italy.

Antonio Canosa (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.
Neurology I, Azienda Ospedaliera Città Della Salute E Della Scienza of Turin, Turin, Italy.

Andrea Calvo (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.
Neurology I, Azienda Ospedaliera Città Della Salute E Della Scienza of Turin, Turin, Italy.

Cristina Moglia (C)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.
Neurology I, Azienda Ospedaliera Città Della Salute E Della Scienza of Turin, Turin, Italy.

Alessandro Cicolin (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.
Sleep Medicine Center, Azienda Ospedaliera Città Della Salute E Della Scienza of Turin, Turin, Italy.

Gabriele Mora (G)

Neurorehabilitation Department, Ics Maugeri Irccs, Institute of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH